| 51 |
Assesment OF complement regulatory protients CD55 and CD59 on erythocytes in Betathalassemia major patients |
2019 |
| 52 |
Assesment OF complement regulatory protients CD55 and CD59 on erythocytes in Betathalassemia major patients |
2019 |
| 53 |
Assessment of the Use of 8 color Flowcytometry in the Diagnosis of Acute Leukemia |
2019 |
| 54 |
Circulating hematopoietic stem cells, endothelial
progenitor cells and cancer stem cells in
hepatocellular carcinoma patients: contribution to
diagnosis and prognosis |
2019 |
| 55 |
Circulating hematopoietic stem cells, endothelial
progenitor cells and cancer stem cells in
hepatocellular carcinoma patients: contribution to
diagnosis and prognosis |
2019 |
| 56 |
Correlation Between the Overall Disease Prognosis and The Percentage of Both (Trisomy 12 and CD49d Expression) in Patients with Chronic Lymphocytic Leukemia (CLL)
|
2019 |
| 57 |
Correlation Between the Overall Disease Prognosis and The Percentage of Both (Trisomy 12 and CD49d Expression) in Patients with Chronic Lymphocytic Leukemia (CLL)
|
2019 |
| 58 |
Correlation Between the Overall Disease Prognosis and The Percentage of Both (Trisomy 12 and CD49d Expression) in Patients with Chronic Lymphocytic Leukemia (CLL)
|
2019 |
| 59 |
Correlation Between the Overall Disease Prognosis and The Percentage of Both (Trisomy 12 and CD49d Expression) in Patients with Chronic Lymphocytic Leukemia (CLL)
|
2019 |
| 60 |
Correlation Between the Overall Disease Prognosis and The Percentage of Both (Trisomy 12 and CD49d Expression) in Patients with Chronic Lymphocytic Leukemia (CLL)
|
2019 |
